Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis of intra-arterial cerebral infusion for glioma patientsDirect Drug Delivery May Help Brain Tumors

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider procedure-related complications occurred in 27.1% of glioma patients receiving intra-arterial infusion.

This systematic review and meta-analysis synthesized data from 230 glioma patients undergoing selective and superselective intra-arterial cerebral infusion with blood-brain barrier disruption. The primary outcomes assessed were safety and efficacy, including procedure-related complications and tumor response rates across the included studies.

Safety data indicated a complication rate of 27.1% (95% CI 19.8% to 35.7%). Procedure-related complications occurred in 15.4% (95% CI 6.1% to 24.6%), with major complications at 4.3% (95% CI 0.9% to 7.7%) and minor complications at 9.7% (95% CI 1.0% to 18.7%). Stroke incidence was 3.1% (95% CI 0% to 6.1%), intracranial hemorrhage was 0.5% (95% CI 0% to 3.2%), and intratumoral hemorrhage was 0.04% (95% CI 0% to 3%). No deaths were reported.

Tumor response varied across the cohort. Complete response was observed in 10.4% (95% CI 0% to 21.5%) of patients, while partial response occurred in 24.2% (95% CI 14.3% to 34.1%). Stable disease was noted in 38.2% (95% CI 21.5% to 54.9%), and disease progression occurred in 39.3% (95% CI 14.8% to 63.8%).

The authors acknowledge limitations, stating further studies are warranted to validate these results and refine procedural protocols. Despite these caveats, the review suggests this approach is a feasible and safe option for glioma treatment. Clinicians should interpret these pooled estimates within the context of the available evidence and consider individual patient factors when evaluating treatment options.

Imagine having a powerful medicine that stays right where it needs to work, instead of traveling through your whole body. This is the promise of a new way to treat brain tumors. Doctors are finding a method that puts high doses of chemotherapy exactly where the cancer is hiding.

Gliomas are a common type of tumor that grows inside the brain. They can be very hard to treat because the skull and a special shield called the blood-brain barrier keep most drugs out. This means standard treatments often fail to kill the cancer cells deep inside.

Patients often face tough choices. They might get very sick from side effects like nausea and hair loss, yet the tumor keeps growing. The current options feel limited and frustrating for families looking for better hope.

The surprising shift

For years, doctors had to choose between giving too little medicine or causing too much harm. But here is the twist: a new technique changes the game. Instead of flooding the body with drugs, doctors use tiny catheters to deliver medicine directly into the arteries feeding the tumor.

They also temporarily open the blood-brain barrier. Think of this shield like a locked door. Usually, medicine cannot get through. This method acts like a master key that opens the door just long enough for the drug to enter, then locks it again.

What scientists didn't expect

The results from recent research are promising. When doctors combined direct delivery with opening the barrier, the treatment seemed safe and effective. Most importantly, there were no deaths directly caused by the procedure. This is a huge relief for patients who fear surgery or invasive treatments.

The study snapshot

Researchers looked at nine different studies involving 230 patients with gliomas. They carefully checked how safe the procedure was and how well it worked against the tumor. They also looked specifically at a more precise version of the technique called superselective infusion.

The good news is that the treatment works for many people. About 10% of patients saw their tumors disappear completely. Another 24% saw the tumor shrink significantly. Even more patients had their disease stay stable for a while.

However, the treatment is not without risks. About 27% of patients experienced some kind of complication. These ranged from minor issues to more serious events like strokes or bleeding. Still, major complications happened in only 4% of cases.

But there's a catch.

This is where things get interesting. The numbers show promise, but they also show that this is not a perfect solution yet. The procedure requires highly skilled doctors and special equipment. Not every hospital can do it right now.

This doesn't mean this treatment is available yet.

Experts say this approach is feasible, but it needs more testing. We need to know exactly which patients benefit most. We also need to figure out the best way to open and close the blood-brain barrier safely every time.

If you or a loved one has a glioma, talk to your doctor about all options. This new method might be an option in specialized centers. It is important to ask if your hospital has the experience to perform this safely.

Do not stop your current treatment without medical advice. This new technique is still being studied. It is not a replacement for standard care yet. It is an addition to the tools doctors have.

More research is needed to make this a standard option. Scientists will look at larger groups of patients to confirm these results. They will also work on making the procedure simpler and safer.

Until then, patients should stay informed. New treatments for brain cancer are always on the horizon. Keeping an open mind and asking questions is the best way to find the right path forward.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Selective and superselective intra-arterial cerebral infusion (SIACI/SSIACI) delivers chemotherapy directly to tumor-supplying arteries, achieving high local drug levels with reduced systemic toxicity. Often combined with blood-brain barrier disruption (BBBd) to enhance penetration, these methods have been widely studied, yet a comprehensive evidence synthesis is lacking. This study systematically assesses the safety and efficacy of intra-arterial chemotherapy with BBBd for glioma treatment. METHODS: We searched PubMed, Embase, and Web of Science for studies on SIACI with BBBd in glioma patients. Safety outcomes included rates of cases with complications, procedure-related complications (major/minor), stroke, intracranial and intratumoral hemorrhage, and mortality. Efficacy was based on tumor response (complete, partial, stable disease, progression). A subanalysis of SSIACI-only cases was also conducted. RESULTS: Nine studies with 230 glioma patients were included. The pooled rate of cases with complications was 27.1% (95% CI 19.8% to 35.7%), with procedure-related complications occurring in 15.4% (95% CI 6.1% to 24.6%). Major and minor complication rates were 4.3% (95% CI 0.9% to 7.7%) and 9.7% (95% CI 1.0% to 18.7%), respectively. Stroke, intracranial hemorrhage, and intratumoral hemorrhage occurred in 3.1% (95% CI 0% to 6.1%), 0.5% (95% CI 0% to 3.2%), and 0.04% (95% CI 0% to 3%), respectively, with no procedure-related deaths reported. Pooled response rates were 10.4% complete (95% CI 0% to 21.5%), 24.2% partial (95% CI 14.3% to 34.1%), 38.2% stable disease (95% CI 21.5% to 54.9%), and 39.3% progression (95% CI 14.8% to 63.8%). Subanalysis of superselective infusions yielded comparable outcomes to the overall cohort. CONCLUSION: The findings indicate that SIACI/SSIACI chemotherapy following BBBd is a feasible and safe approach for glioma treatment, demonstrating a favorable procedural risk profile and preliminary signs of efficacy. Further studies are warranted to validate these results and refine procedural protocols.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.